Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1637 1653
This examiner grants 48% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18640031 | METHODS AND COMPOSITIONS FOR INHIBITING OXIDATIVE STRESS | Non-Final OA | President and Fellows of Harvard College |
| 17924304 | SAFE POTENT SINGLE VECTOR PLATFORM VACCINE AGAINST COVID-19 | Non-Final OA | The Regents of the University of California |
| 18520007 | CAS-READY MOUSE EMBRYONIC STEM CELLS AND MICE AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 16321777 | EXPRESSION OF PTEN-LONG WITH ONCOLYTIC VIRUSES | Non-Final OA | OHIO STATE INNOVATION FOUNDATION |
| 17816061 | Engineered Alum-binding SARS-CoV-2 Immunogens | Final Rejection | Massachusetts Institute of Technology |
| 17929013 | METHODS FOR RAPID CLONING AND EXPRESSION OF HLA CLASS I CELLS | Non-Final OA | Board of Regents, The University of Texas System |
| 17617731 | MEMBRANE ATTACK COMPLEXES AND USES THEREOF | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18088317 | OPTIMIZED GENE EDITING UTILIZING A RECOMBINANT ENDONUCLEASE SYSTEM | Non-Final OA | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 18659841 | COMPOSITIONS AND METHODS FOR HIV QUASI-SPECIES EXCISION FROM HIV-1-INFECTED PATIENTS | Non-Final OA | Drexel University |
| 18009731 | A CELLULAR MARKER OF COVID SEVERITY | Non-Final OA | Sorbonne Universite |
| 18035240 | MODIFIED NK CELLS WITH REDUCED CCR5 EXPRESSION AND METHODS OF THEIR USE | Non-Final OA | The United States of America, as represented by the Secretary, Dept. of Health and Human Services |
| 17932239 | SYNTHETIC MODIFIED VACCINIA ANKARA (sMVA) BASED CORONAVIRUS VACCINES | Final Rejection | CITY OF HOPE |
| 17291199 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AMYOTROPHIC LATERAL SCLEROSIS | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 18525193 | METHOD FOR IDENTIFYING INTERVENTIONS THAT CONTROL THE TRANSLATIONAL ACTIVITY OF RIBOSOMAL PROTEINS IN DIFFERENTIAL MRNA EXPRESSION | Non-Final OA | BREITENBACH-KOLLER, HANNELORE |
| 18366237 | PLATELET TARGETED TREATMENT | Non-Final OA | PLATELET TARGETED THERAPEUTICS, LLC |
| 17429801 | COMPOSITION COMPRISING A MIXTURE OF DNA MOLECULES, USES THEREOF AS BIOLOGICAL INHIBITOR AND METHOD FOR PRODUCTION | Final Rejection | KOPPERT B.V. |
| 18246270 | BIFUNCTIONAL LENTIVIRAL VECTORS ALLOWING THE BS-GLOBIN SILENCING AND EXPRESSION OF AN ANTI-SICKLING HBB AND USES THEREOF FOR GENE THERAPY OF SICKLE CELL DISEASE | Non-Final OA | UNIVERSITÉ DE PARIS |
| 17905315 | Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (SARS) coronavirus infection | Final Rejection | PHYLEX BIOSCIENCES, INC. |
| 18005813 | T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | Non-Final OA | Cue Biopharma, Inc. |
| 18005562 | ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD) | Non-Final OA | XYONE THERAPEUTICS, INC. |
| 18004158 | MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE SAME AND USES THEREOF | Non-Final OA | Immunocell Therapeutics, Inc. |
| 18064219 | ENHANCED IMMUNOGENIC DNA/RNA COMPOSITIONS AND METHODS | Non-Final OA | MBF Therapeutics, Inc. |
| 17927178 | METHOD OF IDENTIFYING OR CHARACTERISING AN IMMUNE RESPONSE IN A SUBJECT | Final Rejection | THE BINDING SITE GROUP LIMITED |
| 17918321 | VACCINES FOR CORONAVIRUS AND METHODS OF USING THE SAME | Non-Final OA | THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY |
| 17796284 | METHODS OF DIAGNOSING AND CLASSIFYING VIRAL INFECTIONS | Final Rejection | MeMed Diagnostics Ltd. |
| 17912525 | METHOD FOR IMPROVING ANTIGEN IMMUNOGENICITY, CORONAVIRUS ANTIGEN, USE THEREOF, RECOMBINANT VECTOR, EXPRESSION KIT, TRANSGENIC CELL LINE, RECOMBINANT BACTERIUM, CORONAVIRUS VACCINE, PREPARATION METHOD OF ANTIGEN AND NUCLEOTIDE SEQUENCE | Non-Final OA | GUANGZHOU QIANYANG BIO-TECHNOLOGY PHARMACEUTICAL CO., LTD. |
| 17398648 | CRISPR-BASED GENOME MODIFICATION AND REGULATION | Final Rejection | Sigma-Aldrich Co. LLC |
| 17759479 | HUMAN ANTI-DENGUE ANTIBODIES AND METHODS OF USE THEREFOR | Non-Final OA | THE REGEBTS OF THE UNIVERSITY OF CALIFORNIA A CALIFORNIA |
| 16544180 | METHOD AND KITS FOR IDENTIFYING OF CDK9 INHIBITORS FOR THE TREATMENT OF CANCER | Final Rejection | St. Jude Children's Research Hospital |
| 17744457 | METHODS FOR INCREASING THE RATE OF GENETIC PROGRESS AND GENERATING INBRED LINES IN NON-HUMAN MAMMALS | Final Rejection | Inguran, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy